A synthetic chemist with a keen focus on synthetic biology, Charlotte leads the Bioconjugation Chemistry team within Biomedical Manufacturing and leads the Industrial Biotechnology domain within the Synthetic Biology Future Science Platform. Charlotte has been with CSIRO since 2009, and regularly engages with biotech and industry, working on commercial research contracts, and collaborating widely with Australian and International Universities. Areas of expertise cover synthetic chemistry and conjugation of small molecules, proteins and antibodies, polymer synthesis and polymer bioconjugation. Charlotte’s Bioconjugation Chemistry team focuses on the orthogonal conjugation of small molecule drugs or polymers to therapeutic proteins, such as antibodies or enzymes. The team seeks to develop new theranostic agents, improve antibody-drug-conjugates, use polymer scaffolds as drug carriers, modify the pharmacokinetics of proteins, and develop new biocatalysts for the pharmaceutical industry. Charlotte gained a Ph.D. in 2002 from The University of Western Australia, followed by postdoctoral research at the University of Oxford, industrial experience followed at Johnson Matthey (UK) and Starpharma Ltd (Australia). The Industrial Biotechnology Application Domain sits at the interface of synthetic biology and chemical manufacturing technologies using synthetic biology to produce high value chemicals for industry, by finding new ways to make or utilise small molecules of high value for agriculture, health/pharma and industrial feedstocks.